

# Mark E Robson

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3884281/mark-e-robson-publications-by-citations.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

256 papers	24,035 citations	75 h-index	151 g-index
281 ext. papers	30,032 ext. citations	9.1 avg, IF	6.3 L-index

#	Paper	IF	Citations
256	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , <b>2017</b> , 23, 703-713	50.5	1638
255	Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 523-533	59.2	1405
254	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. <i>Lancet, The</i> , <b>2010</b> , 376, 235-44	40	1395
253	Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. <i>New England Journal of Medicine</i> , <b>2002</b> , 346, 1609-15	59.2	1198
252	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 443-53	59.2	791
251	Gene-panel sequencing and the prediction of breast-cancer risk. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 2243-57	59.2	587
250	Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. <i>Lancet, The</i> , <b>2000</b> , 356, 1876-81	40	473
249	Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1331-7	2.2	465
248	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , <b>2013</b> , 45, 371-84, 384e1-2	36.3	422
247	Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2012</b> , 21, 134-47	4	411
246	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , <b>2019</b> , 104, 21-34	11	363
245	American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3660-7	2.2	360
244	American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 893-901	2.2	349
243	Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. <i>Cell Stem Cell</i> , <b>2017</b> , 21, 374-382.e4	18	339
242	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. <i>Cancer Cell</i> , <b>2018</b> , 34, 427-438.e4	24.6	339
241	Prediction of breast cancer risk based on profiling with common genetic variants. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	324
240	Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. <i>Science Translational Medicine</i> , <b>2013</b> , 5, 172ra21	17.5	290

239	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 1347-61	27.4	286
238	Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Journal of the National Cancer Institute</i> , <b>2002</b> , 94, 1773-9	9.7	266
237	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. <i>Nature Medicine</i> , <b>2019</b> , 25, 1928-1937	50.5	263
236	OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. <i>Annals of Oncology</i> , <b>2019</b> , 30, 558-566	10.3	240
235	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 318, 825-835	27.4	235
234	A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. <i>Breast Cancer Research</i> , <b>2004</b> , 6, R8-R17	8.3	225
233	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. <i>PLoS Genetics</i> , <b>2013</b> , 9, e1003212	6	209
232	Genome doubling shapes the evolution and prognosis of advanced cancers. <i>Nature Genetics</i> , <b>2018</b> , 50, 1189-1195	36.3	208
231	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 286-295	2.2	203
230	Counselling framework for moderate-penetrance cancer-susceptibility mutations. <i>Nature Reviews Clinical Oncology</i> , <b>2016</b> , 13, 581-8	19.4	200
229	Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. <i>JAMA Oncology</i> , <b>2016</b> , 2, 104-11	13.4	198
228	Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 2115-21	12.9	196
227	Clinical practice. Management of an inherited predisposition to breast cancer. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 154-62	59.2	194
226	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , <b>2017</b> , 49, 680-691	36.3	190
225	An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. <i>Oncologist</i> , <b>2011</b> , 16, 1397-402	5.7	190
224	Multiplex genetic testing for cancer susceptibility: out on the high wire without a net?. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1267-70	2.2	184
223	Tumour lineage shapes BRCA-mediated phenotypes. <i>Nature</i> , <b>2019</b> , 571, 576-579	50.4	170
222	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2141-7	2.2	170

221	Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 4222-7	2.2	169
220	BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 433-8	2.2	160
219	Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. <i>Journal of the National Cancer Institute</i> , <b>2003</b> , 95, 1548-51	9.7	160
218	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	153
217	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. <i>JCO Precision Oncology</i> , <b>2017</b> , 2017,	3.6	151
216	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. <i>JAMA Oncology</i> , <b>2016</b> , 2, 1434-1440	13.4	151
215	BRCA mutations and risk of prostate cancer in Ashkenazi Jews. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 2918-2921	21.9	139
214	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. <i>Human Mutation</i> , <b>2018</b> , 39, 593-620	4.7	138
213	Risk of endometrial carcinoma associated with BRCA mutation. <i>Gynecologic Oncology</i> , <b>2001</b> , 80, 395-8	4.9	135
212	Cancer Risks Associated With Germline Pathogenic Variants: An International Study of 524 Families. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 674-685	2.2	133
211	Diverse and Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 6708-6720	12.9	132
210	Genome-wide association studies of cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4255-67	2.2	127
209	Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. <i>Cancer</i> , <b>2005</b> , 103, 44-51	6.4	123
208	Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 133, 1125-30	4.4	120
207	Identification of germline genetic mutations in patients with pancreatic cancer. <i>Cancer</i> , <b>2015</b> , 121, 4382-8	4.4	117
206	Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. <i>Gynecologic Oncology</i> , <b>2003</b> , 89, 281-7	4.9	111
205	Hereditary breast cancer. <i>Current Problems in Surgery</i> , <b>2001</b> , 38, 387-480	2.8	111
204	Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4071-4078	2.2	110

203	Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2750-60	2.2	107
202	Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis. <i>JAMA Oncology</i> , <b>2017</b> , 3, 1634-1639	13.4	107
201	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 414-424	2.2	107
200	Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 1067-1074	9.7	103
199	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. <i>Nature Genetics</i> , <b>2020</b> , 52, 1219-1226	2.6	103
198	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2240-2250	2.2	101
197	Cancer genomics and inherited risk. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 687-98	2.2	100
196	Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2080-2106	2.2	95
195	Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer. <i>Annals of Surgical Oncology</i> , <b>2013</b> , 20, 3469-76	3.1	95
194	Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers. <i>Journal of the National Cancer Institute</i> , <b>2009</b> , 101, 205-9	9.7	94
193	Screening for germline EGFR T790M mutations through lung cancer genotyping. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 1049-52	8.9	92
192	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4274-4282	2.2	92
191	Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 1250-4	12.9	91
190	Frequency of CHEK2*1100delC in New York breast cancer cases and controls. <i>BMC Medical Genetics</i> , <b>2003</b> , 4, 1	2.1	91
189	Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. <i>PLoS Genetics</i> , <b>2013</b> , 9, e1003173	6	90
188	Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. <i>Cancer</i> , <b>2000</b> , 89, 383-90	6.4	90
187	BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. <i>PLoS Genetics</i> , <b>2018</b> , 14, e1007752	6	90
186	Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. <i>American Journal of Human Genetics</i> , <b>2016</b> , 98, 801-817	11	86

185	Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. <i>Breast Cancer Research</i> , <b>2014</b> , 16, 3419	8.3	82
184	Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. <i>Cancer</i> , <b>2003</b> , 97, 1601-8	6.4	79
183	The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. <i>Npj Breast Cancer</i> , <b>2017</b> , 3, 22	7.8	78
182	A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy. <i>Journal of the American Geriatrics Society</i> , <b>2006</b> , 54, 1115-24	5.6	76
181	A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. <i>Clinical Breast Cancer</i> , <b>2014</b> , 14, 154-60	3	75
180	Genetic analysis of the early natural history of epithelial ovarian carcinoma. <i>PLoS ONE</i> , <b>2010</b> , 5, e10358	3.7	74
179	Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. <i>Annals of Surgical Oncology</i> , <b>2007</b> , 14, 2510-8	3.1	72
178	Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. <i>Cancer</i> , <b>2012</b> , 118, 493-9	6.4	71
177	Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. <i>Breast Cancer Research and Treatment</i> , <b>2006</b> , 98, 343-8	4.4	71
176	Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. <i>Journal of the National Cancer Institute</i> , <b>2005</b> , 97, 1382-4	9.7	70
175	Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 755-63	12.9	69
174	Comparison of screening CEDM and MRI for women at increased risk for breast cancer: A pilot study. <i>European Journal of Radiology</i> , <b>2017</b> , 97, 37-43	4.7	66
173	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , <b>2011</b> , 20, 4693-706	5.6	66
172	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1228-1235	13.4	66
171	The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 1030-1034	9.7	65
170	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	65
169	A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline Mutations (ABRAZO). <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 2717-2724	12.9	65
168	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , <b>2016</b> , 7, 11375	17.4	64



167	Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. <i>BMC Medical Genomics</i> , <b>2017</b> , 10, 33	3.7	64
166	Population Frequency of Germline BRCA1/2 Mutations. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4183-4185.	2.2	64
165	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , <b>2011</b> , 13, R110	8.3	62
164	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , <b>2016</b> , 1, e000097	6	59
163	Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. <i>Cancer Research</i> , <b>2010</b> , 70, 3278-86	10.1	58
162	Health literacy, numeracy, and interpretation of graphical breast cancer risk estimates. <i>Patient Education and Counseling</i> , <b>2011</b> , 83, 92-8	3.1	58
161	Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 3239-3247	12.9	58
160	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , <b>2016</b> , 18, 15	8.3	58
159	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , <b>2020</b> , 52, 56-73	36.3	56
158	Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 163, 565-571	4.4	53
157	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. <i>Journal of the National Cancer Institute</i> , <b>2020</b> , 112, 1242-1250	9.7	51
156	Revealing the incidentalome when targeting the tumor genome. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 310, 795-6	27.4	51
155	Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 2979-85	7.5	51
154	The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1216-22	2.2	51
153	Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2006</b> , 15, 2311-3	4	51
152	American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 986-93	2.2	50
151	Alterations in and promote clinical resistance to alpelisib plus aromatase inhibitors. <i>Nature Cancer</i> , <b>2020</b> , 1, 382-393	15.4	49
150	Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy. <i>Cancer</i> , <b>2012</b> , 118, 4944-52	6.4	49

149	Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). <i>PLoS ONE</i> , <b>2012</b> , 7, e42380	3.7	49
148	Germline EGFR T790M mutation found in multiple members of a familial cohort. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 554-8	8.9	47
147	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , <b>2014</b> , 16, 3416	8.3	46
146	TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression. <i>Molecular Endocrinology</i> , <b>2013</b> , 27, 657-70		42
145	Increased progesterone receptor expression in benign epithelium of BRCA1-related breast cancers. <i>Cancer Research</i> , <b>2004</b> , 64, 5051-3	10.1	42
144	A comparison of bilateral breast cancers in BRCA carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2005</b> , 14, 1534-8	4	42
143	Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 628-33	2.2	41
142	Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1792-3	59.2	39
141	A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients. <i>European Journal of Cancer</i> , <b>2018</b> , 101, 12-19	7.5	39
140	Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies. <i>PLoS Genetics</i> , <b>2013</b> , 9, e1003220	6	38
139	Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2010</b> , 16, 48-52	2.2	38
138	Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes. <i>JAMA Network Open</i> , <b>2020</b> , 3, e208501	10.4	38
137	Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. <i>Cancer</i> , <b>2013</b> , 119, 1344-8	6.4	37
136	Inherited predisposition to gastrointestinal stromal tumor. <i>Hematology/Oncology Clinics of North America</i> , <b>2009</b> , 23, 1-13, vii	3.1	36
135	Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. <i>European Journal of Cancer</i> , <b>2019</b> , 120, 20-30	7.5	35
134	Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life. <i>Gynecologic Oncology</i> , <b>2003</b> , 89, 440-6	4.9	35
133	Ductal lavage in patients undergoing mastectomy for mammary carcinoma: a correlative study. <i>Cancer</i> , <b>2003</b> , 98, 2170-6	6.4	35
132	Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers. <i>Oncogene</i> , <b>2002</b> , 21, 7034-41	9.2	34



131	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , <b>2020</b> , 22, 1653-1666	8.1	34
130	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. <i>PLoS Genetics</i> , <b>2014</b> , 10, e1004256	6	33
129	Genome-wide association studies of cancer predisposition. <i>Hematology/Oncology Clinics of North America</i> , <b>2010</b> , 24, 973-96	3.1	33
128	Breast MRI for women with hereditary cancer risk. <i>JAMA - Journal of the American Medical Association</i> , <b>2004</b> , 292, 1368-70	27.4	33
127	Clinical considerations in the management of individuals at risk for hereditary breast and ovarian cancer. <i>Cancer Control</i> , <b>2002</b> , 9, 457-65	2.2	33
126	Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. <i>Steroids</i> , <b>2015</b> , 99, 32-8	2.8	32
125	Evaluation of germline PTEN mutations in endometrial cancer patients. <i>Gynecologic Oncology</i> , <b>2005</b> , 96, 21-4	4.9	32
124	Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer. <i>BJU International</i> , <b>2012</b> , 109, 713-9	5.6	31
123	Hereditary ovarian cancer in Ashkenazi Jews. <i>Familial Cancer</i> , <b>2004</b> , 3, 259-64	3	31
122	Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?. <i>BMC Medicine</i> , <b>2014</b> , 12, 140	11.4	30
121	COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. <i>Breast Cancer Research</i> , <b>2013</b> , 15, 402	8.3	30
120	A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. <i>Future Oncology</i> , <b>2017</b> , 13, 307-320	3.6	30
119	A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer. <i>Cancer Discovery</i> , <b>2016</b> , 6, 1267-1275	24.4	30
118	Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 5754-61	12.9	29
117	Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status. <i>Cancer</i> , <b>2016</b> , 122, 1178-84	6.4	29
116	Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women@ Environmental Cancer and Radiation Epidemiology Study. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1513-1520	2.2	29
115	A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 3398-407	12.9	28
114	The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds. <i>Familial Cancer</i> , <b>2005</b> , 4, 177-81	3	28

113	Adjuvant treatment recommendations in older women with breast cancer: a survey of oncologists. <i>Critical Reviews in Oncology/Hematology</i> , <b>2007</b> , 61, 255-60	7	27
112	Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. <i>PLoS ONE</i> , <b>2015</b> , 10, e0120020	3.7	26
111	BRCA mutations in women with ductal carcinoma in situ. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 4306-10	12.9	26
110	Genetic Testing Awareness and Attitudes among Latinos: Exploring Shared Perceptions and Gender-Based Differences. <i>Public Health Genomics</i> , <b>2016</b> , 19, 34-46	1.9	26
109	Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?. <i>Breast Cancer Research and Treatment</i> , <b>2013</b> , 138, 273-9	4.4	25
108	Assessment of SLX4 Mutations in Hereditary Breast Cancers. <i>PLoS ONE</i> , <b>2013</b> , 8, e66961	3.7	24
107	Germline PALB2 mutation analysis in breast-pancreas cancer families. <i>Journal of Medical Genetics</i> , <b>2011</b> , 48, 523-5	5.8	24
106	Functional redundancy of exon 12 of BRCA2 revealed by a comprehensive analysis of the c.6853A>G (p.I2285V) variant. <i>Human Mutation</i> , <b>2009</b> , 30, 1543-50	4.7	24
105	Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 177, 61-66	4.4	23
104	Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 114, 127-35	4.4	23
103	Breast cancer surveillance in women with hereditary risk due to BRCA1 or BRCA2 mutations. <i>Clinical Breast Cancer</i> , <b>2004</b> , 5, 260-8; discussion 269-71	3	23
102	Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up. <i>Cancer</i> , <b>2005</b> , 104, 314-20	6.4	23
101	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. <i>Nature Cancer</i> , <b>2021</b> , 2, 357-365	15.4	23
100	Association of Common Genetic Variants With Contralateral Breast Cancer Risk in the WECARE Study. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	22
99	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , <b>2020</b> , 80, 624-638	10.1	22
98	The 6q22.33 locus and breast cancer susceptibility. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2009</b> , 18, 2468-75	4	22
97	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , <b>2019</b> , 111, 350-364	9.7	22
96	Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4224-6	2.2	21

95	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2015</b> , 24, 308-16	4	20
94	Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1398-1408	2.2	20
93	A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. <i>Genetics in Medicine</i> , <b>2018</b> , 20, 1324-1327	8.1	20
92	Germline mutations in children and adults with cancer. <i>Journal of Physical Education and Sports Management</i> , <b>2018</b> , 4,	2.8	20
91	Histopathologic characteristics of background parenchymal enhancement (BPE) on breast MRI. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 172, 487-496	4.4	20
90	Homologous recombination DNA repair defects in associated breast cancers. <i>Npj Breast Cancer</i> , <b>2019</b> , 5, 23	7.8	20
89	Rare de novo germline copy-number variation in testicular cancer. <i>American Journal of Human Genetics</i> , <b>2012</b> , 91, 379-83	11	20
88	A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2012</b> , 21, 1362-70	4	20
87	Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report. <i>Journal of Medical Genetics</i> , <b>2019</b> , 56, 347-357	5.8	19
86	Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis. <i>Breast Cancer Research and Treatment</i> , <b>2013</b> , 139, 497-506	4.4	18
85	Estrogen receptor-beta expression in hereditary breast cancer. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 3752-3; author reply 3753	2.2	18
84	Risks to relatives in genomic research: a duty to warn?. <i>American Journal of Bioethics</i> , <b>2012</b> , 12, 12-4	1.1	17
83	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , <b>2015</b> , 17, 61	8.3	16
82	Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations. <i>Genetics in Medicine</i> , <b>2001</b> , 3, 422-5	8.1	16
81	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2698-2709	2.2	16
80	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 161, 117-134	4.4	15
79	Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 123, 581-5	4.4	15
78	Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 655-660	8.9	14

77	Endometrial Cancers in or Germline Mutation Carriers: Assessment of Homologous Recombination DNA Repair Defects. <i>JCO Precision Oncology</i> , <b>2019</b> , 3,	3.6	14
76	SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 164, 189-199	4.4	13
75	Broad Application of Multigene Panel Testing for Breast Cancer Susceptibility-Pandora® Box Is Opening Wider. <i>JAMA Oncology</i> , <b>2019</b> ,	13.4	13
74	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. <i>British Journal of Cancer</i> , <b>2019</b> , 121, 180-192	8.7	13
73	Germline mutations detected in pediatric sequencing studies impact parents' evaluation and care. <i>Journal of Physical Education and Sports Management</i> , <b>2017</b> , 3,	2.8	13
72	New pharmacogenomic paradigm in breast cancer treatment. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4665-6	5.6	13
71	Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 162, 297-306	4.4	12
70	Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 160, 447-456	4.4	12
69	Mosaic partial deletion of the PTEN gene in a patient with Cowden syndrome. <i>Familial Cancer</i> , <b>2014</b> , 13, 459-67	3	12
68	Treatment of hereditary breast cancer. <i>Seminars in Oncology</i> , <b>2007</b> , 34, 384-91	5.5	12
67	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. <i>Journal of the National Cancer Institute</i> , <b>2021</b> ,	9.7	12
66	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.. <i>Cell</i> , <b>2022</b> , 185, 563-575.e11	56.2	11
65	Fumarate hydratase FH c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma. <i>Human Mutation</i> , <b>2020</b> , 41, 103-109	4.7	11
64	Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma. <i>Modern Pathology</i> , <b>2020</b> , 33, 2221-2232	9.8	10
63	Protecting the privacy of third-party information: recommendations for social and behavioral health researchers. <i>Social Science and Medicine</i> , <b>2007</b> , 64, 213-22	5.1	10
62	Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 223-7	12.9	10
61	The genomic landscape of metastatic histologic special types of invasive breast cancer. <i>Npj Breast Cancer</i> , <b>2020</b> , 6, 53	7.8	10
60	Yoga for Chemotherapy-Induced Peripheral Neuropathy and Fall Risk: A Randomized Controlled Trial. <i>JNCI Cancer Spectrum</i> , <b>2020</b> , 4, pkaa048	4.6	10

59	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , <b>2021</b> , 11, 2796-2811	24.4	10
58	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. <i>Genetic Epidemiology</i> , <b>2020</b> , 44, 442-468	2.6	9
57	Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With /CEP17 Ratio . <i>Archives of Pathology and Laboratory Medicine</i> , <b>2020</b> , 144, 597-601	5	9
56	Educational and Psychosocial Support Needs in Lynch Syndrome: Implementation and Assessment of an Educational Workshop and Support Group. <i>Journal of Genetic Counseling</i> , <b>2017</b> , 26, 232-243	2.5	8
55	What women with breast cancer discuss with clinicians about risk for their adolescent daughters. <i>Journal of Psychosocial Oncology</i> , <b>2012</b> , 30, 484-502	2.8	8
54	Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible. <i>Clinical Breast Cancer</i> , <b>2008</b> , 8, 418-24	3	8
53	The Landscape of Somatic Genetic Alterations in Breast Cancers from Germline Mutation Carriers. <i>JNCI Cancer Spectrum</i> , <b>2019</b> , 3, pkz027	4.6	7
52	Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families. <i>Breast Cancer Research and Treatment</i> , <b>2014</b> , 145, 625-34	4.4	7
51	Identification and Functional Characterization of V769M, a Novel Germline Variant Associated With Multiple Lung Adenocarcinomas. <i>JCO Precision Oncology</i> , <b>2017</b> , 1,	3.6	7
50	Juvenile polyposis syndrome presenting with familial gastric cancer and massive gastric polyposis. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e229-32	2.2	7
49	Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action. <i>JCI Insight</i> , <b>2020</b> , 5,	9.9	7
48	Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 96	7.8	7
47	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2102767	2.2	7
46	Protein-altering germline mutations implicate novel genes related to lung cancer development. <i>Nature Communications</i> , <b>2020</b> , 11, 2220	17.4	6
45	Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer. <i>Journal of the National Cancer Institute</i> , <b>2020</b> , 112, 1275-1279	9.7	6
44	The context-specific role of germline pathogenicity in tumorigenesis. <i>Nature Genetics</i> , <b>2021</b> , 53, 1577-1585	35.3	6
43	PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer. <i>The Cochrane Library</i> , <b>2021</b> , 4, CD011395	5.2	6
42	Pilot study of rapid MR pancreas screening for patients with BRCA mutation. <i>European Radiology</i> , <b>2019</b> , 29, 3976-3985	8	5

41	Differences between screen-detected and interval breast cancers among BRCA mutation carriers. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 175, 141-148	4.4	5
40	RE: BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis. <i>Journal of the National Cancer Institute</i> , <b>2019</b> , 111, 522-523	9.7	5
39	Inherited predisposition to cancer: introduction and overview. <i>Hematology/Oncology Clinics of North America</i> , <b>2010</b> , 24, 793-7	3.1	5
38	Long-term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer. <i>Cancer Medicine</i> , <b>2021</b> , 10, 5163-5174	4.8	5
37	Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomised controlled trial. <i>BMJ Open</i> , <b>2019</b> , 9, e031092	3	5
36	Characterization of a novel germline BRCA1 splice variant, c.5332+4delA. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 168, 543-550	4.4	5
35	Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.. <i>JAMA Oncology</i> , <b>2022</b> ,	13.4	5
34	Illustrating Cancer Risk: Patient Risk Communication Preferences and Interest regarding a Novel BRCA1/2 Genetic Risk Modifier Test. <i>Public Health Genomics</i> , <b>2020</b> , 23, 6-19	1.9	4
33	Decision-Making Preferences About Secondary Germline Findings That Arise From Tumor Genomic Profiling Among Patients With Advanced Cancers. <i>JCO Precision Oncology</i> , <b>2017</b> , 1,	3.6	4
32	Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPL2. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 106, 219-227	6.1	4
31	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. <i>Nature Communications</i> , <b>2021</b> , 12, 1078	17.4	4
30	Breast cancer: oophorectomy for BRCA1 ER--negative disease-an open debate. <i>Nature Reviews Clinical Oncology</i> , <b>2015</b> , 12, 505-6	19.4	3
29	Prevalence and Characterization of Biallelic and Monoallelic and Variant Carriers From a Pan-Cancer Patient Population. <i>JCO Precision Oncology</i> , <b>2021</b> , 5,	3.6	3
28	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , <b>2021</b> ,	9.7	3
27	A Novel Adverse Event Associated with Olaparib Therapy in a Patient with Metastatic Breast Cancer. <i>Case Reports in Oncological Medicine</i> , <b>2018</b> , 2018, 9529821	0.9	2
26	The Role of Genetic Counseling in Familial and Sporadic Cancer: Considerations, Challenges, and Collaboration. <i>Annals of Internal Medicine</i> , <b>2017</b> , 167, 884-885	8	2
25	Seizing the Opportunity: Recognition and Management of Hereditary Cancer Predisposition. <i>Seminars in Oncology</i> , <b>2007</b> , 34, 367-368	5.5	2
24	Is breast conservation a reasonable option for women with BRCA-associated breast cancer?. <i>Nature Clinical Practice Oncology</i> , <b>2007</b> , 4, 10-1		2



23	Frequency of actionable cancer predisposing germline mutations in patients with lung cancers.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1504-1504	2.2	2
22	Penetrance of male breast cancer susceptibility genes: a systematic review. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 1	4.4	2
21	Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. <i>JCO Precision Oncology</i> , <b>2020</b> , 4,	3.6	2
20	Comprehensive Breast Cancer Risk Assessment for and Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model. <i>JCO Precision Oncology</i> , <b>2021</b> , 5,	3.6	2
19	PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays. <i>American Journal of Surgical Pathology</i> , <b>2021</b> , 45, 1274-1281	6.7	2
18	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. <i>Genetics in Medicine</i> , <b>2021</b> , 23, 1726-1737	8.1	2
17	Response. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	2
16	Understanding inherited risk in unselected newly diagnosed patients with endometrial cancer. <i>JCO Precision Oncology</i> , <b>2019</b> , 3,	3.6	2
15	Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer. <i>Genetics in Medicine</i> , <b>2021</b> , 23, 2105-2113	8.1	2
14	Oncology Patients' Perspectives on Remote Patient Monitoring for COVID-19. <i>JCO Oncology Practice</i> , <b>2021</b> , 17, e1278-e1285	2.3	2
13	Reply to R.L. Nussbaum et al and J.S. Dolinsky et al. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1262-1263	2.2	1
12	Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers. <i>Gynecologic Oncology</i> , <b>2021</b> , 161, 521-526	4.9	1
11	Tolerability of Breast Radiotherapy Among Carriers of Germline Variants. <i>JCO Precision Oncology</i> , <b>2021</b> , 5,	3.6	1
10	Management of Women With Breast Cancer and Pathogenic Variants in Genes Other Than or. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2528-2534	2.2	1
9	Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination. <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 135	7.8	0
8	Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab.. <i>Npj Breast Cancer</i> , <b>2022</b> , 8, 37	7.8	0
7	Moderate-Penetrance Predisposition to Breast Cancer. <i>Current Breast Cancer Reports</i> , <b>2018</b> , 10, 232-239	0.8	
6	Understanding the Paradigm Challenges Posed by Multiplex Panel Testing for Cancer Susceptibility. <i>Current Genetic Medicine Reports</i> , <b>2014</b> , 2, 250-254	2.2	

5 Genetic Epidemiology of Breast Cancer **2013**, 1113-1125

- 4 Considerations in genetic counseling for inherited breast cancer predisposition. *Seminars in Radiation Oncology*, **2002**, 12, 362-70 5.5
- 3 Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer. *Pharmacogenetics and Genomics*, **2021**, 31, 1-9 1.9
- 2 The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriersK.A. Metcalfe, H.T. Lynch, P. Ghadirian, N. Tung, I.A. Olivotto, W.D. Foulkes, E. Warner, O. Olopade, A. Eisen, B. Weber, et al. *Gynecol Oncol* 2005;96:222-26. *Womens Oncology Review*, **2005**, 5, 163-164
- 1 Next-Generation Sequencing of Matched Normal Blood Identifies Clonal Hematopoiesis in a Significant Subset of Solid Tumor Patients without Hematologic Malignancies. *Blood*, **2015**, 126, 2447-2457 2.2